Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Proteomics Company to Build Clinical Trials Infrastructure

NEW YORK, March 19 – Toronto-based proteomics company Syn X Pharma said Monday it would build the infrastructure to conduct in-house clinical trials.

The company, which recently hired a proteomics executive from Ciphergen and a business development expert from Eli Lilly, said the move signaled its efforts to begin bringing its products to market.

"This is a significant step for Syn X Pharma as we move towards commercialization of our products," Sean McNicholas, the company’s CEO, said in a statement. "By building this capability internally we will be able to shorten the time to market for all of our products, both diagnostic and therapeutic, developed using our proprietary Proteomics Discovery platform.”

That Proteomics Discovery system is used to identify protein targets that can be used to develop new drugs and antibody-based diagnostics.

The company has hired Leah Im as clinical trials project manager. Her first assignment will be to start the trial for strokepanel, a point-of-care blood test to diagnose stroke. Syn X is also in the process of developing diagnostics for diabetes, cardiovascular diseases, including heart failure and hypertension, and central nervous system diseases such as Alzheimer's.

Syn X did not comment on the amount of money it would invest to build the clinical trials capabilities. A spokesperson was not immediately available for comment.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.